NYSE
6 days, 16 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova (K)
The W.K. Kellogg Foundation Trust sold 114,583 shares of Kellanova (K) at a price of $82.2574 per share on April 21, 2025, according to a Form 4 filing.

NYSE
13 days, 15 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells Shares of Kellanova (K) Under 10b5-1 Plan
The W.K. Kellogg Foundation Trust sold 114,583 shares of Kellanova (K) at a price of $82.4121 per share on April 14, 2025, according to a Form 4 filing.

NYSE
20 days, 14 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova (K)
The W.K. Kellogg Foundation Trust sold 114,583 shares of Kellanova (K) at a price of $82.0297 per share on April 7, 2025, according to a Form 4 filing.

NYSE
30 days, 16 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova (K)
The W.K. Kellogg Foundation Trust sold 114,583 shares of Kellanova (K) at a price of $82.4386 per share on March 28, 2025, according to a Form 4 filing.

NYSE
37 days, 15 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova (K) Under 10b5-1 Plan
The W.K. Kellogg Foundation Trust sold 114,583 shares of Kellanova (K) common stock at a price of $82.3071 per share on March 21, 2025, according to a Form 4 filing.

NYSE
44 days, 16 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova (K) at $82.26
The W.K. Kellogg Foundation Trust sold 114,583 shares of Kellanova (K) common stock at a price of $82.2554 per share on March 14, 2025, reducing its holdings to 47,618,280 shares.

NYSE
46 days, 15 hours ago 
K
Kellanova
8-K: Kellanova Secures Mars Guarantee for Senior Notes Following Merger Consent Solicitations
Kellanova successfully obtains Mars' guarantee for its senior notes through consent solicitations, contingent on the completion of their merger.

NYSE
51 days, 14 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova (K)
The W.K. Kellogg Foundation Trust sold 114,583 shares of Kellanova (K) at a price of $82.5498 per share on March 7, 2025, according to a Form 4 filing.

NYSE
51 days, 15 hours ago 
K
Kellanova
10-K/A: Kellanova Files Amendment to 10-K, Providing Detailed Executive Compensation and Governance Information
Kellanova's amended 10-K filing includes comprehensive details on director and executive compensation, corporate governance practices, and related party transactions for the fiscal year ended December 28, 2024.

NYSE
58 days, 15 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova (K)
The W.K. Kellogg Foundation Trust sold 114,583 shares of Kellanova common stock at a price of $82.6978 per share on February 28, 2025, according to a Form 4 filing.

NYSE
59 days, 15 hours ago 
K
Kellanova
8-K: Kellanova Announces RSU Grants to Named Executive Officers
Kellanova's Board of Directors approved restricted stock unit (RSU) grants to its named executive officers on February 21, 2025, under the Kellanova 2022 Long-Term Incentive Plan.

NYSE
61 days, 14 hours ago 
K
Kellanova
Form 4: Kellanova Senior Vice President Nicolas Amaya Reports Acquisition of Restricted Stock Units
Senior Vice President Nicolas Amaya reports the acquisition of restricted stock units and adjustments to common stock holdings.

NYSE
61 days, 14 hours ago 
K
Kellanova
Form 4: Kellanova Executive Charisse Ford Hughes Reports Acquisition of Restricted Stock Units
Senior Vice President Charisse Ford Hughes reports the acquisition of 9,320 restricted stock units of Kellanova common stock.

NYSE
61 days, 14 hours ago 
K
Kellanova
Form 4: Kellanova Senior Vice President Howell Melissa A Reports Acquisition of Restricted Stock Units
Senior Vice President Howell Melissa A reports acquisition of 19,600 restricted stock units in Kellanova.

NYSE
61 days, 14 hours ago 
K
Kellanova
Form 4: Kellanova Executive David Lawlor Reports Acquisition of Restricted Stock Units
Senior Vice President David Lawlor reports the acquisition of restricted stock units in Kellanova.

NYSE
61 days, 14 hours ago 
K
Kellanova
Form 4: Kellanova Executive Kris Bahner Reports Acquisition of Restricted Stock Units
Kris Bahner, SVP-Chief Global Corporate Affairs at Kellanova, reports the acquisition of 8,720 restricted stock units on February 21, 2025.

NYSE
61 days, 14 hours ago 
K
Kellanova
Form 4: Kellanova Senior Vice President Shumit Kapoor Reports Acquisition of Restricted Stock Units
Senior Vice President of Kellanova, Shumit Kapoor, reports the acquisition of 18,880 restricted stock units.

NYSE
61 days, 14 hours ago 
K
Kellanova
Form 4: Kellanova Chairman and CEO Steven Cahillane Reports Acquisition of Restricted Stock Units
Steven Cahillane, Chairman and CEO of Kellanova, reports the acquisition of 118,560 restricted stock units.

NYSE
61 days, 14 hours ago 
K
Kellanova
Form 4: Kellanova Senior Vice President Acquires Restricted Stock Units
Senior Vice President Victor Marroquin acquired 8,470 restricted stock units of Kellanova common stock on February 21, 2025, which vest on February 21, 2028.

NYSE
61 days, 14 hours ago 
K
Kellanova
Form 4: Kellanova Executive Amit Banati Reports Stock Transactions
Senior Vice President Amit Banati reports acquisition of restricted stock units and disposal of common stock.

NYSE
61 days, 14 hours ago 
K
Kellanova
Form 4: Kellanova Senior Vice President Lance Rodrigo Reports Acquisition of Restricted Stock Units
Senior Vice President Lance Rodrigo reports acquisition of Kellanova restricted stock units and updates beneficial ownership.

NYSE
61 days, 14 hours ago 
K
Kellanova
Form 4: Kellanova Executive Kurt D Forche Reports Acquisition of Restricted Stock Units
Kurt D Forche, VP-Corporate Controller of Kellanova, reports the acquisition of restricted stock units and updates to beneficial ownership of common stock.

NYSE
61 days, 14 hours ago 
K
Kellanova
Form 4: Kellanova Chief Legal Officer Reports Acquisition of Restricted Stock Units
Todd W. Haigh, Chief Legal Officer of Kellanova, reports the acquisition of 17,790 restricted stock units and adjustments to common stock holdings.

NYSE
62 days, 14 hours ago 
K
Kellanova
Form 4: Kellanova Senior Vice President Amit Banati Reports Stock Transactions
Senior Vice President Amit Banati reports acquisition and disposal of Kellanova common stock and derivative securities, including transactions related to stock options and restricted stock units.

NYSE
62 days, 14 hours ago 
K
Kellanova
Form 4: Kellanova Executive Kris Bahner Reports Stock Transactions
Kris Bahner, SVP-Chief Global Corporate Affairs at Kellanova, reports the acquisition and disposal of common stock and derivative securities.

NYSE
62 days, 14 hours ago 
K
Kellanova
Form 4: Kellanova Executive Nicolas Amaya Reports Stock Transactions
Nicolas Amaya, a Senior Vice President at Kellanova, reported the acquisition and disposal of company stock and derivative securities.

NYSE
62 days, 14 hours ago 
K
Kellanova
Form 4: Kellanova Senior Vice President Victor Marroquin Reports Stock Transactions
Senior Vice President Victor Marroquin reports transactions involving Kellanova stock, including the exercise of stock options and restricted stock units, as well as the disposition of shares to cover tax obligations.

NYSE
62 days, 15 hours ago 
K
Kellanova
Form 4: Kellanova Chief Legal Officer Reports Stock Transactions
Todd W. Haigh, Chief Legal Officer of Kellanova, reports the acquisition and disposal of common stock and derivative securities.

NYSE
62 days, 15 hours ago 
K
Kellanova
Form 4: Kellanova Executive Lance Rodrigo Reports Stock Transactions
Senior Vice President Lance Rodrigo reports exercising stock options and restricted stock units, and disposing of shares to cover taxes.

NYSE
62 days, 15 hours ago 
K
Kellanova
Form 4: Kellanova Executive David Lawlor Reports Stock Transactions
David Lawlor, a Senior Vice President at Kellanova, reported the acquisition and disposal of company stock and derivative securities.

NYSE
62 days, 15 hours ago 
K
Kellanova
Form 4: Kellanova Chairman and CEO Steven Cahillane Reports Stock Transactions
Steven Cahillane, Chairman and CEO of Kellanova, reports the vesting and disposal of restricted stock units.

NYSE
62 days, 15 hours ago 
K
Kellanova
Form 4: Kellanova Executive Kurt D Forche Reports Stock Transactions
Kellanova's VP-Corporate Controller, Kurt D Forche, reports the disposition of shares to cover tax obligations upon vesting of restricted stock units.

NYSE
62 days, 15 hours ago 
K
Kellanova
Form 4: Kellanova Senior Vice President Howell Reports Stock Transactions
Melissa A. Howell, Senior Vice President of Kellanova, reports the acquisition and disposal of company stock and restricted stock units on February 21, 2025.

NYSE
62 days, 15 hours ago 
K
Kellanova
Form 4: Kellanova Senior Vice President Charisse Ford Hughes Reports Stock Transactions
Charisse Ford Hughes, a Senior Vice President at Kellanova, reported the acquisition and disposal of company stock and restricted stock units on February 21, 2025.

NYSE
62 days, 15 hours ago 
K
Kellanova
Form 4: Kellanova Senior Vice President Shumit Kapoor Reports Stock Unit Transaction
Senior Vice President Shumit Kapoor of Kellanova reports the disposition of 26,401 common stock units on February 21, 2025.

NYSE
65 days, 15 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova (K)
The W.K. Kellogg Foundation Trust sold 114,583 shares of Kellanova (K) at a price of $82.5005 per share on February 21, 2025, according to a Form 4 filing.

NYSE
65 days, 15 hours ago 
K
Kellanova
10-K: Kellanova's 2024 10-K Filing: Merger Pending, Snacks Lead Growth Amidst Macroeconomic Headwinds
Kellanova's 2024 results highlight a pending merger with Mars, a focus on snacks-led growth, and navigation of complex macroeconomic conditions following the spin-off of WK Kellogg Co.
Delay expected
 
Worse than expected
 

NYSE
66 days, 13 hours ago 
K
Kellanova
Form 4: Kellanova Executive Victor Marroquin Reports Stock Transactions
Senior Vice President Victor Marroquin reports the disposition of Kellanova stock and restricted stock units on February 18, 2025.

NYSE
66 days, 13 hours ago 
K
Kellanova
Form 4: Kellanova Executive Rodrigo Lance Reports Stock Transactions
Senior Vice President Rodrigo Lance reports the vesting and disposal of restricted stock units and shares of Kellanova common stock.

NYSE
66 days, 13 hours ago 
K
Kellanova
Form 4: Kellanova Executive David Lawlor Reports Stock Transactions
David Lawlor, a Senior Vice President at Kellanova, reported the vesting and subsequent disposal of restricted stock units on February 18, 2025.

NYSE
66 days, 13 hours ago 
K
Kellanova
Form 4: Kellanova Senior Vice President Shumit Kapoor Reports Stock Transactions
Senior Vice President of Kellanova, Shumit Kapoor, reports the acquisition and disposal of common stock and restricted stock units on February 18, 2025.

NYSE
66 days, 13 hours ago 
K
Kellanova
Form 4: Kellanova Executive Charisse Ford Hughes Reports Stock Transactions
Senior Vice President Charisse Ford Hughes of Kellanova reports the acquisition and disposal of common stock and restricted stock units on February 18, 2025.

NYSE
66 days, 13 hours ago 
K
Kellanova
Form 4: Kellanova Executive Howell Reports Stock Transactions
Senior Vice President Melissa A. Howell of Kellanova reports the vesting and subsequent sale of restricted stock units.

NYSE
66 days, 13 hours ago 
K
Kellanova
Form 4: Kellanova Chief Legal Officer Reports Stock Transactions
Todd W. Haigh, Chief Legal Officer of Kellanova, reports the acquisition and disposal of company stock and restricted stock units on February 18, 2025.

NYSE
66 days, 13 hours ago 
K
Kellanova
Form 4: Kellanova VP-Corporate Controller Kurt D Forche Reports Stock Transactions
Kurt D Forche, VP-Corporate Controller of Kellanova, reports the acquisition and disposal of common stock and restricted stock units on February 18, 2025.

NYSE
66 days, 13 hours ago 
K
Kellanova
Form 4: Kellanova Chairman and CEO Steven Cahillane Reports Stock Transactions
Steven Cahillane, Chairman and CEO of Kellanova, reports the acquisition and disposal of company stock and restricted stock units on February 18, 2025.

NYSE
66 days, 13 hours ago 
K
Kellanova
Form 4: Kellanova Senior Vice President Amit Banati Reports Stock Transactions
Senior Vice President Amit Banati of Kellanova reports the acquisition and disposal of common stock and restricted stock units on February 18, 2025.

NYSE
66 days, 13 hours ago 
K
Kellanova
Form 4: Kellanova SVP-Chief Global Corp Affairs, Kris Bahner, Reports Stock Transactions
Kris Bahner, SVP-Chief Global Corp Affairs at Kellanova, reports the vesting and subsequent sale of restricted stock units.

NYSE
66 days, 13 hours ago 
K
Kellanova
Form 4: Kellanova Executive Nicolas Amaya Reports Stock Transactions
Senior Vice President Nicolas Amaya reports the acquisition and disposal of Kellanova common stock and restricted stock units on February 18, 2025.

NYSE
72 days, 15 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova (K)
The W.K. Kellogg Foundation Trust sold 114,583 shares of Kellanova (K) at a price of $82.2528 per share on February 14, 2025, according to a Form 4 filing.

NYSE
72 days, 15 hours ago 
K
Kellanova
Form 4: Kellanova Director Stephanie Burns Reports Changes in Beneficial Ownership
Director Stephanie Burns reports a transaction involving phantom stock units and indirect ownership of common stock in Kellanova.

NYSE
72 days, 15 hours ago 
K
Kellanova
Form 4: Kellanova Director Gund Reports Changes in Beneficial Ownership
Director G. Zachary Gund reports changes in beneficial ownership of Kellanova shares, including acquisitions of phantom stock units and holdings in various trusts and partnerships.

NYSE
76 days, 15 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova (K)
The W.K. Kellogg Foundation Trust sold 114,583 shares of Kellanova (K) at a price of $82.2309 per share on February 10, 2025, according to a Form 4 filing.

NYSE
81 days, 0 hours ago 
K
Kellanova
8-K: Kellanova Reports Strong Q4 and Full Year 2024 Results Amidst Pending Mars Acquisition
Kellanova announced strong fourth quarter and full year 2024 results, marked by organic growth and improved profitability, while preparing for its acquisition by Mars, Incorporated.
Better than expected
 

NYSE
89 days, 15 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova (K)
The W.K. Kellogg Foundation Trust sold 114,583 shares of Kellanova (K) at a price of $81.9092 per share on January 28, 2025, according to a Form 4 filing.

NYSE
96 days, 14 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova (K)
The W.K. Kellogg Foundation Trust sold 114,583 shares of Kellanova (K) at a price of $81.6862 per share on January 21, 2025, according to a Form 4 filing.

NYSE
103 days, 14 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova
The Kellogg W K Foundation Trust sold 114,583 shares of Kellanova stock at a price of $81.4214 per share on January 14, 2025.

NYSE
110 days, 13 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova Stock
The W.K. Kellogg Foundation Trust sold 114,583 shares of Kellanova stock at a price of $81.2809 per share on January 7, 2025.

NYSE
118 days, 15 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova (K)
The W.K. Kellogg Foundation Trust sold 114,583 shares of Kellanova (K) at a price of $80.8464 per share on December 30, 2024, according to a Form 4 filing with the SEC.

NYSE
125 days, 15 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells Shares of Kellanova (K) Under 10b5-1 Plan
The W.K. Kellogg Foundation Trust sold 114,583 shares of Kellanova (K) at a price of $80.6424 per share on December 23, 2024, according to a Form 4 filing.

NYSE
132 days, 15 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova Stock
The Kellogg W K Foundation Trust sold 114,583 shares of Kellanova stock at a price of $80.6892 per share on December 16, 2024.

NYSE
136 days, 15 hours ago 
K
Kellanova
8-K: Kellanova Secures $750 Million Credit Facility, Replacing Existing Agreement
Kellanova has entered into a new $750 million unsecured 364-Day Credit Agreement, replacing its previous facility and providing funds for general corporate purposes.

NYSE
139 days, 14 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova Stock
The W.K. Kellogg Foundation Trust sold 114,583 shares of Kellanova stock at a price of $80.6986 per share on December 9, 2024.

NYSE
149 days, 18 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova Stock
The Kellogg W K Foundation Trust sold 114,583 shares of Kellanova stock at a price of $81.2129 per share on November 29, 2024.

NYSE
157 days, 15 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova Stock
The Kellogg W K Foundation Trust sold 114,583 shares of Kellanova stock at a price of $80.9916 per share on November 21, 2024.

NYSE
160 days, 15 hours ago 
K
Kellanova
Form 4: Kellanova Executive Kris Bahner Reports Stock Transactions
Kellanova's SVP-Chief Global Corporate Affairs, Kris Bahner, reported the acquisition and disposal of company stock and restricted stock units on November 16, 2024.

NYSE
164 days, 15 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova Stock
The Kellogg W K Foundation Trust sold 114,583 shares of Kellanova stock at a price of $81.0448 per share.

NYSE
164 days, 15 hours ago 
K
Kellanova
Form 4: Kellanova Director Stephanie Burns Reports Acquisition of Phantom Stock Units
Director Stephanie Burns of Kellanova reported the acquisition of 162.82 phantom stock units, as well as holding 31,293.436 common shares in trust.

NYSE
164 days, 15 hours ago 
K
Kellanova
Form 4: Kellanova Director G. Zachary Gund Reports Acquisition of Phantom Stock Units
Director G. Zachary Gund reported the acquisition of 325.64 phantom stock units in Kellanova, along with holdings of common stock through various trusts and partnerships.

NYSE
171 days, 15 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova (K)
The W.K. Kellogg Foundation Trust sold 114,583 shares of Kellanova (K) at a price of $80.8862 per share on November 7, 2024, according to a Form 4 filing with the SEC.

NYSE
175 days, 2 hours ago 
K
Kellanova
8-K: Kellanova Shareowners Approve Merger with Acquiror 10VB8, LLC
Kellanova shareholders have approved the merger agreement with Acquiror 10VB8, LLC, paving the way for the company to become a wholly-owned subsidiary.

NYSE
179 days, 0 hours ago 
K
Kellanova
10-Q: Kellanova Reports Q3 2024 Results Amidst Proposed Merger
Kellanova's Q3 2024 results show a slight decrease in net sales but an increase in operating profit, while the company navigates a proposed merger with Mars, Incorporated.
Better than expected
 
Delay expected
 

NYSE
179 days, 1 hours ago 
K
Kellanova
DEFA14A: Kellanova Reports Strong Q3 Results Amidst Pending Acquisition by Mars
Kellanova announced strong third-quarter results, driven by organic growth and improved profitability, while awaiting shareholder approval for its acquisition by Mars, Incorporated.
Better than expected
 

NYSE
179 days, 1 hours ago 
K
Kellanova
8-K: Kellanova Reports Strong Q3 Results Amidst Pending Mars Acquisition
Kellanova announced strong third-quarter results for 2024, marked by double-digit operating profit and earnings per share growth, while a merger with Mars, Incorporated is pending.
Better than expected
 

NYSE
181 days, 15 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova (K)
The W.K. Kellogg Foundation Trust sold 114,583 shares of Kellanova (K) at a price of $80.7609 per share on October 28, 2024, according to a Form 4 filing.

NYSE
188 days, 14 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova (K)
The W.K. Kellogg Foundation Trust sold 114,583 shares of Kellanova (K) at a price of $80.9598 per share on October 21, 2024, according to a Form 4 filing.

NYSE
188 days, 16 hours ago 
K
Kellanova
DEFA14A: Kellanova Addresses Lawsuits and Demand Letters Related to Mars Merger with Supplemental Disclosures
Kellanova is supplementing its definitive proxy statement with additional disclosures to address claims made in lawsuits and demand letters regarding the proposed merger with Mars, Incorporated.

NYSE
188 days, 16 hours ago 
K
Kellanova
8-K: Kellanova Amends Proxy Statement Following Merger Lawsuits and Shareholder Demands
Kellanova has supplemented its definitive proxy statement related to its merger with Acquiror 10VB8, LLC, following lawsuits and demand letters from shareholders alleging misrepresentations and omissions.
Worse than expected
 

NYSE
194 days, 15 hours ago 
K
Kellanova
Form 4: Kellogg W K Foundation Trust Sells 114,583 Shares of Kellanova (K)
The W.K. Kellogg Foundation Trust sold 114,583 shares of Kellanova (K) at a price of $80.6254 per share on October 14, 2024, according to a Form 4 filing.

NYSE
198 days, 16 hours ago 
K
Kellanova
DEFA14A: Kellanova Urges Stockholders to Vote on Proposed Merger
Kellanova is soliciting proxies for a special meeting of stockholders to approve a proposed merger, with voting directions due by October 29, 2024.

K 
Kellanova 
NYSE

8-K: Kellanova Amends Proxy Statement Following Merger Lawsuits and Shareholder Demands

Sentiment:
 Merger Update
 21 October 2024 4:14 PM

Kellanova has supplemented its definitive proxy statement related to its merger with Acquiror 10VB8, LLC, following lawsuits and demand letters from shareholders alleging misrepresentations and omissions.

Worse than expected
  The document indicates that the company is facing lawsuits and demand letters, which suggests that the initial proxy statement was not well-received by some shareholders.  The need for supplemental disclosures implies that the initial disclosures were inadequate or misleading, which is a negative development. 

Summary
  • Kellanova has amended its definitive proxy statement in response to three lawsuits and eleven demand letters from shareholders.
  • The lawsuits allege that the proxy statement misrepresents or omits material information regarding financial projections, financial advisor analyses, and potential conflicts of interest.
  • The complaints seek to halt the merger unless additional information is disclosed, or to obtain damages and legal fees.
  • Kellanova maintains that the claims are without merit but has chosen to supplement the proxy statement to avoid further delays and expenses.
  • The supplemental disclosures include additional details regarding the background of the merger, the discounted cash flow analysis, selected publicly traded companies analysis, selected precedent transactions analysis, and premia paid analysis performed by financial advisors Lazard and Goldman Sachs.
  • The company has added a statement clarifying that no post-closing employment arrangements were discussed with senior management prior to the board's approval of the merger agreement.
  • The amended proxy statement includes revised ranges for equity value per share based on various financial analyses, including discounted cash flow, comparable company multiples, and precedent transactions.
Sentiment

Score: 4

Explanation: The sentiment is negative due to the lawsuits and demand letters, indicating shareholder dissatisfaction and potential risks to the merger. However, the company is taking steps to address the issues, which mitigates some of the negativity.

Highlights
  • Kellanova is facing three lawsuits and eleven demand letters from shareholders regarding its proposed merger.
  • The lawsuits allege misrepresentations and omissions in the definitive proxy statement, particularly concerning financial projections and advisor analyses.
  • Lazard's discounted cash flow analysis implied an equity value per share range of $69.60 to $79.10.
  • Lazard's selected publicly traded companies analysis indicated an equity value per share range of $57.20 to $75.70.
  • Lazard's selected precedent transactions analysis implied an equity value per share range of $78.10 to $90.20.
  • Lazard's premia paid analysis implied an equity value per share range of $75.60 to $85.10.
  • Goldman Sachs' discounted cash flow analysis resulted in an equity value per share range of $68.42 to $83.82.
  • Goldman Sachs' present value of future share price analysis resulted in an equity value per share range of $60.93 to $90.01.
  • Goldman Sachs' premia paid analysis resulted in an equity value per share range of $67.39 to $83.13.
  • Goldman Sachs' precedent transaction multiples analysis resulted in an equity value per share range of $58.81 to $118.63.
  • The merger agreement is still subject to shareholder approval at a special meeting scheduled for November 1, 2024.
Positives
  • Kellanova is proactively addressing shareholder concerns by supplementing the proxy statement.
  • The company is providing additional transparency regarding the financial analyses conducted by its advisors.
  • The supplemental disclosures aim to moot the disclosure claims and avoid potential business delays.
Negatives
  • The lawsuits and demand letters indicate shareholder dissatisfaction with the initial proxy statement.
  • The allegations of misrepresentation and omission could potentially delay or disrupt the merger.
  • The need for supplemental disclosures suggests potential weaknesses in the initial proxy statement.
Risks
  • The outcome of the lawsuits and demand letters is uncertain.
  • Additional lawsuits and demand letters may be filed in the future.
  • The merger may not be completed if the conditions are not satisfied or if the shareholder vote fails.
  • The merger could be delayed or terminated due to regulatory hurdles or other unforeseen circumstances.
  • The company faces potential costs and business disruptions due to the litigation and supplemental disclosures.
Future Outlook

The company is seeking shareholder approval for the merger at a special meeting on November 1, 2024, and the merger is subject to various conditions and regulatory approvals.

Management Comments
  • The Company believes the claims asserted in the Merger Actions and Demand Letters are without merit but cannot predict the outcome of any such claims.
  • While the Company believes that the disclosures set forth in the Definitive Proxy Statement comply fully with all applicable laws and denies the allegations in the Merger Actions and Demand Letters, in order to moot the disclosure claims, and avoid nuisance and possible expense and business delays, the Company has determined voluntarily to supplement certain disclosures in the Definitive Proxy Statement related to the claims with the supplemental disclosures set forth below.
Industry Context

The merger is occurring within the food industry, where consolidation and acquisitions are common. The financial analysis includes comparisons to other snacking and diversified grocery companies, as well as precedent transactions in the sector.

Comparison to Industry Standards
  • Lazard's analysis included a comparison to companies like PepsiCo, Mondelz International, and The Hershey Company in the snacking sector, and The Kraft Heinz Company, General Mills, and Conagra Brands in the diversified grocery sector.
  • The precedent transactions analysis included deals such as J.M. Smucker's acquisition of Hostess Brands and Campbell Soup Company's acquisition of Sovos Brands.
  • Goldman Sachs' analysis included a review of 50 all-cash or cash-and-stock acquisition transactions involving U.S. publicly traded target companies with a transaction value equal to or greater than $20 billion.
  • The multiples used in the analysis, such as EV/EBITDA and price/EPS, are standard metrics used in the food industry for valuation purposes.
Stakeholder Impact
  • Shareholders are impacted by the potential delay or termination of the merger and the legal proceedings.
  • Employees may be affected by the uncertainty surrounding the merger.
  • Customers and suppliers may experience disruptions due to the ongoing situation.
Next Steps
  • Kellanova will hold a special meeting of shareholders on November 1, 2024, to vote on the merger.
  • The company will continue to address the lawsuits and demand letters.
  • The company will seek to satisfy all conditions necessary to complete the merger.
Legal Proceedings
  • Two complaints have been filed in the Supreme Court of the State of New York, County of New York, captioned Dan Smith v. Kellanova, et. al., and Steve Taylor vs. Kellanova, et. al.
  • One complaint has been filed in the Circuit Court of Cook County, Illinois, County Department, Chancery Division, captioned Dana L. Crosby vs. Kellanova, et. al.
  • The lawsuits allege misrepresentations and omissions in the definitive proxy statement and seek to enjoin the merger or obtain damages.
  • The company has also received demand letters from 11 purported shareholders seeking additional disclosures.
Key Dates
  • 2024-08-02: Last trading day before media reports of a potential transaction with Mars became public.
  • 2024-08-12: Date used for share counts and other data in financial analysis.
  • 2024-08-13: Date Kellanova entered into the Merger Agreement with Acquiror 10VB8, LLC.
  • 2024-09-26: Date the company filed the definitive proxy statement with the SEC.
  • 2024-10-09: Date the Crosby Complaint was filed in the Circuit Court of Cook County, Illinois.
  • 2024-10-11: Date the Smith and Taylor Complaints were filed in the Supreme Court of the State of New York.
  • 2024-10-21: Date of the 8-K filing and supplemental disclosures.
  • 2024-11-01: Date of the special meeting of Kellanova's shareholders to vote on the merger.
Keywords
Merger, Kellanova, Proxy Statement, Lawsuits, Shareholder Demands, Financial Analysis, Lazard, Goldman Sachs, Discounted Cash Flow, Valuation, Acquisition

K 
Kellanova 
NYSE
Sector: TBD
 
Filings with Classifications
Delay expected
21 February 2025 4:16 PM

Annual Results
  • The exact timing of the completion of the Merger, if at all, cannot be predicted with any certainty.
Worse than expected
21 February 2025 4:16 PM

Annual Results
  • Net sales decreased 2.8% year-over-year, indicating a decline in overall revenue.
Better than expected
6 February 2025 8:02 AM

Earnings Release
  • The company's organic growth exceeded expectations.
  • Profit margins improved faster than anticipated.
  • Earnings per share showed double-digit growth.
Better than expected
31 October 2024 8:10 AM

Quarterly Report
  • The company's operating profit increased by 10% year-over-year, indicating better than expected profitability.
  • Diluted EPS increased by 84% to $1.05, showing better than expected earnings.
  • Currency-neutral adjusted operating profit increased by 19%, demonstrating better than expected underlying performance.
Delay expected
31 October 2024 8:10 AM

Quarterly Report
  • The merger with Mars is expected to close in the first half of 2025, but the exact timing cannot be predicted with certainty, indicating a potential delay.
Better than expected
31 October 2024 8:09 AM

Financial News Release
  • Kellanova's Q3 results exceeded expectations with double-digit operating profit growth and strong earnings per share growth.
  • Organic net sales growth of 6.1% surpassed the company's long-term target range.
Better than expected
31 October 2024 8:08 AM

Quarterly Report
  • The company's organic net sales growth of 6.1% exceeded expectations.
  • The company's double-digit operating profit growth was better than expected.
  • The company's earnings per share growth was better than expected.
Worse than expected
21 October 2024 4:14 PM

Merger Update
  • The document indicates that the company is facing lawsuits and demand letters, which suggests that the initial proxy statement was not well-received by some shareholders.
  • The need for supplemental disclosures implies that the initial disclosures were inadequate or misleading, which is a negative development.
Better than expected
14 August 2024 5:11 PM

Merger Announcement
  • The acquisition price of $83.50 per share represents a significant premium over the recent trading price of Kellanova stock, indicating a better-than-expected outcome for shareholders.
Capital raise
14 August 2024 7:32 AM

Merger Announcement
  • Mars intends to fully finance the acquisition through a combination of cash-on-hand and new debt, for which commitments have been secured.
Better than expected
14 August 2024 7:25 AM

Merger Announcement
  • The acquisition price represents a significant premium over Kellanova's recent trading price, indicating a better than expected outcome for shareholders.
Better than expected
1 August 2024 4:15 PM

Quarterly Report
  • The company's operating profit increased by 18% year-over-year, indicating better than expected profitability.
  • Currency-neutral adjusted operating profit increased by 16%, showing better than expected operational performance.
  • Diluted EPS increased by 17.6% to $1.00, and currency-neutral adjusted diluted EPS increased by 14.4% to $1.03, both better than expected.
Better than expected
1 August 2024 8:03 AM

Quarterly Report
  • Kellanova's results exceeded expectations due to strong organic growth, improved profitability, and increased full-year guidance.
Capital raise
16 May 2024 4:31 PM

Debt Offering Announcement
  • Kellanova raised $300 million through the issuance of 5.750% Senior Notes due 2054.
  • Kellanova also raised 300 million through the issuance of 3.750% Senior Notes due 2034.
Capital raise
9 May 2024 4:59 PM

Debt Offering Announcement
  • Kellanova raised $600 million through the issuance of senior notes.
  • The offering was split between $300 million in USD denominated notes and 300 million in EUR denominated notes.
Better than expected
2 May 2024 4:13 PM

Quarterly Report
  • The company's currency-neutral adjusted operating profit increased by 30%, indicating better than expected operational performance.
  • Currency-neutral adjusted diluted EPS grew by 33%, reflecting better than expected earnings growth.
Better than expected
2 May 2024 8:02 AM

Quarterly Report
  • The company's adjusted operating profit and earnings per share growth exceeded expectations, driven by improved profit margins and effective cost management.
  • The company's free cash flow generation was significantly better than the prior year, indicating improved financial health.
  • The company's reaffirmation of full-year guidance, despite adverse currency movements, suggests confidence in its underlying performance.
Delay expected
20 February 2024 4:20 PM

Annual Results
  • The document mentions that supply pressures are generally decreasing, though weather and geopolitical issues are resulting in other disruptions and logistical delays into 2024.
Better than expected
20 February 2024 4:20 PM

Annual Results
  • The company's organic net sales growth of 8.3% exceeded expectations.
  • The company's operating profit increased by 24.3%, indicating better than expected profitability.
  • The company's currency-neutral adjusted diluted EPS of $3.18 was better than expected.
Better than expected
8 February 2024 8:06 AM

Quarterly Report
  • The company's fourth-quarter results exceeded previous guidance for net sales, operating profit, and earnings per share.

Disclaimer: This summary was generated by artificial intelligence and its accuracy is not guaranteed. The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.